<DOC>
	<DOCNO>NCT00352313</DOCNO>
	<brief_summary>RATIONALE : ATN-161 may stop growth tumor cell block blood flow tumor . Drugs use chemotherapy , carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving ATN-161 together carboplatin may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose ATN-161 give together carboplatin see well work treat patient recurrent malignant glioma .</brief_summary>
	<brief_title>ATN-161 Carboplatin Treating Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Establish safety ATN-161 carboplatin patient recurrent intracranial malignant glioma . - Determine maximum tolerate dose ATN-161 administer carboplatin patient . ( phase I ) - Determine antitumor activity ATN-161 administer carboplatin patient . ( phase II ) Secondary - Describe effect regimen potential biomarkers activity , include functional imaging brain perfusion scan circulate endothelial progenitor cell . - Obtain preliminary evidence efficacy regimen patient . ( phase I ) - Characterize plasma concentration regimen patient . ( phase I ) OUTLINE : This open-label , phase I dose-escalation study ATN-161 follow phase II study . Patients phase II portion study stratify accord tumor type ( glioblastoma multiforme v anaplastic glioma ) . - Phase I : Patients receive ATN-161 IV 10 minute 3 time weekly week 1-6 carboplatin IV 20 minute week 3 course 1 . Beginning course 2 , patient receive carboplatin IV 20 minute week 1 ATN-161 IV 10 minute 3 time weekly week 1-4 . Treatment repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos ATN-161 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity first 6 week treatment . - Phase II : Patients receive carboplatin IV week 1 ATN-161 IV , MTD determine phase I , 3 time weekly week 1-4 . Treatment repeat every 4 week 12 course absence disease progression unacceptable toxicity . Patients undergo blood collection baseline periodically phase I course 1 pharmacokinetic pharmacodynamic analysis baseline periodically study biomarker ( e.g. , circulate endothelial progenitor cell ) correlative study . After completion study treatment , patient follow 28 day . PROJECTED ACCRUAL : A total 82 patient accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm intracranial malignant glioma Original lowgrade glioma histology allow provided subsequent histologic confirmation malignant glioma Any follow diagnosis : Glioblastoma multiforme Gliosarcoma Anaplastic astrocytoma Anaplastic oligodendroglioma Anaplastic mix oligoastrocytoma Malignant astrocytoma otherwise specify Recurrent disease Must fail prior radiotherapy Must confirmation true progressive disease ( rather radiation necrosis ) base upon either positron emission tomography thallium scanning , MR spectroscopy , surgical documentation disease radiographic recurrence within highdose radiation field ( patient underwent prior interstitial brachytherapy stereotactic radiosurgery ) Prior recent resection recurrent progressive tumor allow follow criterion meet : Recovered prior surgery Evaluable disease resection Unequivocal evidence tumor progression MRI Steroid dose must stable ≥ 5 day prior MRI PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Life expectancy &gt; 8 week WBC ≥ 3,000/mm³ Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL ( transfusion allow ) AST &lt; 2.5 time upper limit normal ( ULN ) Bilirubin &lt; 2.5 time ULN Creatinine &lt; 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month completion study treatment No significant medical illness would preclude study treatment No history cancer ( except nonmelanoma skin cancer carcinoma situ cervix ) unless disease complete remission therapy ≥ 1 year No active infection serious intercurrent medical illness No disease obscure toxicity dangerously alter drug metabolism Able undergo MRI scan receive contrast agent perfusion scan PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy At least 28 day since prior cytotoxic therapy At least 14 day since prior vincristine At least 42 day since prior nitrosoureas At least 21 day since prior procarbazine At least 7 day since prior interferon , tamoxifen , thalidomide , isotretinoin , noncytotoxic agent ( radiosensitizer count ) At least 14 day since prior noncytotoxic investigational agent At least 42 day since prior radiotherapy No prior cisplatin , carboplatin , oxaliplatin , platinumcontaining analogue No concurrent prophylactic filgrastim ( GCSF ) sargramostim ( GMCSF ) No concurrent anticancer therapy ( include chemotherapy , radiotherapy , hormonal therapy , immunotherapy ) No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
</DOC>